{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T09:37:55Z","timestamp":1787823475190,"version":"build-2784847793"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1007\/s40265-016-0581-4","type":"journal-article","created":{"date-parts":[[2016,5,5]],"date-time":"2016-05-05T11:03:11Z","timestamp":1462446191000},"page":"869-878","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Eltrombopag: A Review in Paediatric Chronic Immune Thrombocytopenia"],"prefix":"10.1007","volume":"76","author":[{"given":"Celeste B.","family":"Burness","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian M.","family":"Keating","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karly P.","family":"Garnock-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,5,5]]},"reference":[{"issue":"11","key":"581_CR1","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","volume":"113","author":"F Rodeghiero","year":"2009","unstructured":"Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386\u201393.","journal-title":"Blood"},{"issue":"2","key":"581_CR2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00431-013-2254-6","volume":"173","author":"V Labarque","year":"2014","unstructured":"Labarque V, Van Geet C. Clinical practice: immune thrombocytopenia in paediatrics. Eur J Pediatr. 2014;173(2):163\u201372.","journal-title":"Eur J Pediatr"},{"issue":"16","key":"581_CR3","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1182\/blood-2010-08-302984","volume":"117","author":"C Neunert","year":"2011","unstructured":"Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190\u2013207.","journal-title":"Blood"},{"issue":"2","key":"581_CR4","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood-2009-06-225565","volume":"115","author":"D Provan","year":"2010","unstructured":"Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168\u201386.","journal-title":"Blood"},{"issue":"10","key":"581_CR5","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.2165\/11207390-000000000-00000","volume":"71","author":"KP Garnock-Jones","year":"2011","unstructured":"Garnock-Jones KP. Eltrombopag: a review of its use in treatment-refractory chronic primary immune thrombocytopenia. Drugs. 2011;71(10):1333\u201353.","journal-title":"Drugs."},{"key":"581_CR6","unstructured":"GlaxoSmithKline. Promacta\u00ae (eltrombopag): US prescribing information. 2015. https:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/promacta.pdf . Accessed 17 Mar 2016."},{"key":"581_CR7","unstructured":"European Medicines Agency. Revolade\u2122 (eltrombopag): EU summary of product characteristics. 2016. http:\/\/www.ema.europa.eu . Accessed 26 Apr 2016."},{"issue":"16","key":"581_CR8","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1007\/s40265-014-0312-7","volume":"74","author":"CB Burness","year":"2014","unstructured":"Burness CB. Eltrombopag: a review of its use in the treatment of thrombocytopenia in patients with chronic hepatitis C. Drugs. 2014;74(16):1961\u201371.","journal-title":"Drugs."},{"issue":"5","key":"581_CR9","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s40265-015-0363-4","volume":"75","author":"PL McCormack","year":"2015","unstructured":"McCormack PL. Eltrombopag: a review of its use in patients with severe aplastic anaemia. Drugs. 2015;75(5):525\u201331.","journal-title":"Drugs."},{"issue":"2","key":"581_CR10","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1634\/stemcells.2008-0366","volume":"27","author":"CL Erickson-Miller","year":"2009","unstructured":"Erickson-Miller CL, Delorme E, Tian SS, et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells. 2009;27(2):424\u201330.","journal-title":"Stem Cells"},{"issue":"11","key":"581_CR11","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1182\/blood-2006-11-057968","volume":"109","author":"JM Jenkins","year":"2007","unstructured":"Jenkins JM, Williams D, Deng Y, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood. 2007;109(11):4739\u201341.","journal-title":"Blood"},{"issue":"8","key":"581_CR12","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1016\/S2352-3026(15)00114-3","volume":"2","author":"JB Bussel","year":"2015","unstructured":"Bussel JB, De Miguel PG, Despotovic JM. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Lancet Haematol. 2015;2(8):e315\u201325.","journal-title":"Lancet Haematol."},{"key":"581_CR13","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/S0140-6736(15)61107-2","volume":"386","author":"JD Grainger","year":"2015","unstructured":"Grainger JD, Locatelli F, Chotsampancharoen T, et al. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. Lancet. 2015;386:1649\u201358.","journal-title":"Lancet"},{"issue":"22","key":"581_CR14","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa073275","volume":"357","author":"JB Bussel","year":"2007","unstructured":"Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357(22):2237\u201347.","journal-title":"N Engl J Med"},{"issue":"9","key":"581_CR15","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.exphem.2009.06.011","volume":"37","author":"JA Erhardt","year":"2009","unstructured":"Erhardt JA, Erickson-Miller CL, Aivado M, et al. Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function. Exp Hematol. 2009;37(9):1030\u20137.","journal-title":"Exp Hematol"},{"issue":"17","key":"581_CR16","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1182\/blood-2011-11-393900","volume":"119","author":"B Psaila","year":"2012","unstructured":"Psaila B, Bussel JB, Linden MD, et al. In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation. Blood. 2012;119(17):4066\u201372.","journal-title":"Blood"},{"issue":"1","key":"581_CR17","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1365-2125.2010.03646.x","volume":"70","author":"G Matthys","year":"2010","unstructured":"Matthys G, Park JW, McGuire S, et al. Eltrombopag does not affect cardiac repolarization: results from a definitive QTc study in healthy subjects. Br J Clin Pharmacol. 2010;70(1):24\u201333.","journal-title":"Br J Clin Pharmacol"},{"key":"581_CR18","unstructured":"FDA. Clinical pharmacology review. 2015. http:\/\/www.fda.gov\/ . Accessed 17 Mar 2016."},{"issue":"3","key":"581_CR19","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/0091270010368677","volume":"51","author":"G Matthys","year":"2011","unstructured":"Matthys G, Park JW, McGuire S, et al. Clinical pharmacokinetics, platelet response, and safety of eltrombopag at supratherapeutic doses of up to 200\u00a0mg once daily in healthy volunteers. J Clin Pharmacol. 2011;51(3):301\u20138.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"581_CR20","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.clinthera.2012.01.011","volume":"34","author":"MB Wire","year":"2012","unstructured":"Wire MB, Bruce J, Gauvin J, et al. A randomized, open-label, 5-period, balanced crossover study to evaluate the relative bioavailability of eltrombopag powder for oral suspension (PfOS) and tablet formulations and the effect of a high-calcium meal on eltrombopag pharmacokinetics when administered with or 2 hours before or after PfOS. Clin Ther. 2012;34(3):699\u2013709.","journal-title":"Clin Ther"},{"issue":"4","key":"581_CR21","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.clinthera.2009.04.010","volume":"31","author":"DD Williams","year":"2009","unstructured":"Williams DD, Peng B, Bailey CK, et al. Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies. Clin Ther. 2009;31(4):764\u201376.","journal-title":"Clin Ther"},{"issue":"21","key":"581_CR22","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1182\/blood.V124.21.1450.1450","volume":"124","author":"JB Bussel","year":"2014","unstructured":"Bussel JB, Grainger JD, de Miguel PG, et al. PETIT and PETIT 2: treatment with eltrombopag in 171 children with chronic immune thrombocytopenia (ITP) [abstract]. Blood. 2014;124(21):1450.","journal-title":"Blood"},{"issue":"9763","key":"581_CR23","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0140-6736(10)60959-2","volume":"377","author":"G Cheng","year":"2011","unstructured":"Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011;377(9763):393\u2013402.","journal-title":"Lancet"},{"issue":"21","key":"581_CR24","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.1182\/blood.V124.21.4206.4206","volume":"124","author":"JD Grainger","year":"2014","unstructured":"Grainger JD, Routledge DJM, Kruse A, et al. Thrombopoietin receptor agonists in paediatric ITP patients: long term follow up data in 34 patients [abstract]. Blood. 2014;124(21):4206.","journal-title":"Blood"},{"issue":"18","key":"581_CR25","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1182\/blood-2009-05-224766","volume":"114","author":"DJ Kuter","year":"2009","unstructured":"Kuter DJ, Mufti GJ, Bain BJ, et al. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood. 2009;114(18):3748\u201356.","journal-title":"Blood"},{"key":"581_CR26","unstructured":"FDA. Clinical review: Promacta\u00ae (eltrombopag) tablets. 2015. http:\/\/www.fda.gov\/ . Accessed 17 Mar 2016 2016."},{"issue":"21","key":"581_CR27","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1182\/blood.V122.21.3559.3559","volume":"122","author":"CE McGuinn","year":"2013","unstructured":"McGuinn CE, Imahiyerobo A, Thompson M, et al. Safety and efficacy of eltrombopag at escalated doses up to 150\u00a0mg in patients with persistent and chronic immune thrombocytopenia (ITP) not responsive to 75\u00a0mg [abstract]. Blood. 2013;122(21):3559.","journal-title":"Blood"},{"issue":"5","key":"581_CR28","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3324\/haematol.2013.098921","volume":"99","author":"W Ghanima","year":"2014","unstructured":"Ghanima W, Geyer JT, Lee CS, et al. Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up. Haematologica. 2014;99(5):937\u201344.","journal-title":"Haematologica"},{"issue":"11","key":"581_CR29","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1111\/trf.12139","volume":"53","author":"B Ghadaki","year":"2013","unstructured":"Ghadaki B, Nazi I, Kelton JG, et al. Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists. Transfusion. 2013;53(11):2807\u201312.","journal-title":"Transfusion."},{"issue":"6","key":"581_CR30","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/bjh.12888","volume":"165","author":"M Mahevas","year":"2014","unstructured":"Mahevas M, Fain O, Ebbo M, et al. The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study. Br J Haematol. 2014;165(6):865\u20139.","journal-title":"Br J Haematol"},{"key":"581_CR31","unstructured":"Amgen Inc. Nplate\u00ae (romiplostim), for subcutaneous injection: US prescribing information. 2014. http:\/\/www.nplate.com\/ . Accessed 17 Mar 2016."},{"key":"581_CR32","unstructured":"European Medicines Agency. Nplate (romiplostim): EU summary of product characteristics. 2015. http:\/\/www.ema.europa.eu . Accessed 17 Mar 2016."},{"issue":"1","key":"581_CR33","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2010-10-313908","volume":"118","author":"JB Bussel","year":"2011","unstructured":"Bussel JB, Buchanan GR, Nugent DJ, et al. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood. 2011;118(1):28\u201336.","journal-title":"Blood"},{"issue":"11","key":"581_CR34","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s00277-011-1172-9","volume":"90","author":"MS Elalfy","year":"2011","unstructured":"Elalfy MS, Abdelmaksoud AA, Eltonbary KY. Romiplostim in children with chronic refractory ITP: randomized placebo controlled study. Ann Hematol. 2011;90(11):1341\u20134.","journal-title":"Ann Hematol"},{"issue":"1","key":"581_CR35","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/bjh.13266","volume":"169","author":"JR Gonzalez-Porras","year":"2015","unstructured":"Gonzalez-Porras JR, Mingot-Castellano ME, Andrade MM, et al. Use of eltrombopag after romiplostim in primary immune thrombocytopenia. Br J Haematol. 2015;169(1):111\u20136.","journal-title":"Br J Haematol"},{"issue":"5","key":"581_CR36","first-page":"511","volume":"56","author":"M Mori","year":"2015","unstructured":"Mori M, Kato M, Koh K, et al. Successful switching from eltrombopag to romiplostim in a pediatric patient with refractory chronic ITP. Rinsho Ketsueki. 2015;56(5):511\u20133.","journal-title":"Rinsho Ketsueki."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0581-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-016-0581-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0581-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T12:43:52Z","timestamp":1600519432000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-016-0581-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["581"],"URL":"https:\/\/doi.org\/10.1007\/s40265-016-0581-4","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5]]}}}